Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load
Yegnasew Takele,
Tadele Mulaw,
Emebet Adem,
Rebecca Womersley,
Myrsini Kaforou,
Susanne Ursula Franssen,
Michael Levin,
Graham Philip Taylor,
Ingrid Müller,
James Anthony Cotton,
Pascale Kropf
Affiliations
Yegnasew Takele
Department of Infectious Disease, Imperial College London, London, UK; Leishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia
Tadele Mulaw
Leishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia
Emebet Adem
Leishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia
Rebecca Womersley
Department of Infectious Disease, Imperial College London, London, UK
Myrsini Kaforou
Department of Infectious Disease, Imperial College London, London, UK
Susanne Ursula Franssen
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK
Michael Levin
Department of Infectious Disease, Imperial College London, London, UK
Graham Philip Taylor
Department of Infectious Disease, Imperial College London, London, UK
Ingrid Müller
Department of Infectious Disease, Imperial College London, London, UK
James Anthony Cotton
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK
Pascale Kropf
Department of Infectious Disease, Imperial College London, London, UK; Corresponding author
Summary: Visceral leishmaniasis (VL) and HIV co-infection (VL/HIV) has emerged as a significant public health problem in Ethiopia, with up to 30% of patients with VL co-infected with HIV. These patients suffer from recurrent VL relapses and increased mortality. Those with a previous history of VL relapses (recurrent VL/HIV) experience increased VL relapses as compared to patients with HIV presenting with their first episode of VL (primary VL/HIV). Our aim was to identify drivers that account for the higher rate of VL relapses in patients with recurrent VL/HIV (n = 28) as compared to primary VL/HIV (n = 21). Our results show that the relapse-free survival in patients with recurrent VL/HIV was shorter, that they had higher parasite load, lower weight gain, and lower recovery of all blood cell lineages. Their poorer prognosis was characterized by lower production of IFN-gamma, lower CD4+ T cell counts, and higher expression of programmed cell death protein 1 (PD1) on T cells.
